GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · Real-Time Price · USD
0.2260
+0.0060 (2.73%)
Apr 22, 2025, 2:46 PM EDT - Market open
GlycoMimetics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
14.58M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GLYC News
- 19 days ago - Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - GlobeNewsWire
- 6 weeks ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - PRNewsWire
- 7 weeks ago - Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 5 months ago - Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - PRNewsWire
- 5 months ago - GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - Business Wire
- 6 months ago - GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC - Business Wire
- 6 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - PRNewsWire
- 6 months ago - GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire